
    
      EG-70 is a novel non-viral gene therapy. EG-70 is designed to elicit a local immune response
      following delivery of gene therapies to mucosal tissues, such as the bladder urothelium. This
      approach of local administration through bladder instillation has the potential to induce a
      potent immune response exclusively at the site of the tumor, resulting in greater therapeutic
      benefit while reducing undesirable systemic toxicity.
    
  